# Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCC

> **NCT05485896** · PHASE2 · COMPLETED · sponsor: **Tianjin Medical University Second Hospital** · enrollment: 23 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Pembrolizumab plus Lenvatinib

## Key facts

- **NCT ID:** NCT05485896
- **Lead sponsor:** Tianjin Medical University Second Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-09-02
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05485896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05485896, "Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05485896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*